US Market Report for BPH Treatment Devices 2016 - MedCore
The prostate is a gland that is approximately the size of a walnut. It surrounds the urethra and is located in front of the rectum, just below the bladder. Beginning at approximately age 25, the prostate enters a phase of continuous growth that can lead to a condition called benign prostatic hyperplasia (BPH) later in life.
BPH is caused by the natural behavior of the prostate: as the prostate enlarges, the surrounding capsule stops it from expanding outwards, pressing it against the urethra, which thereby becomes obstructed in many cases. The bladder wall thickens and becomes irritable, leading to more frequent urination, especially at night. As a result of the obstruction, the bladder eventually weakens and loses its ability to fully empty, resulting in incomplete voiding and residual urine.
While symptoms of BPH are rarely exhibited before the age of 40, this condition affects approximately 50% of men in their 50s, 80% of men in their 70s and over 95% of men over 80 years of age. In the U.S., approximately 25% of men will receive some form of treatment for BPH in their lifetime.
Early symptoms of BPH include frequent urination and reduced urine flow. Over time, BPH can result in more serious complications such as acute urinary retention, urinary tract infections (UTIs), bladder or kidney damage, stones and incontinence.This report groups laser BPH procedures into the following categories: PVP, laser enucleation and other laser procedures. The reason for this is because there is a distinct CPT code for laser enucleation procedures which require the use of a morcellator. There is also a specific code for laser vaporization procedures that includes PVP procedures which represent the largest share of laser BPH procedures. Taking the difference between laser enucleation and PVP procedures yields the proportion of other laser procedures which includes laser ablation, laser resection, etc.